Unlabelled: Thyroid-like follicular carcinoma of the kidney (TLFC), a rare neoplasm with low malignant potential, is histologically similar to primary thyroid follicular carcinoma, but characteristically lacks thyroid immunohistochemical markers. We report a case of 34-year old patient with nephrolithiasis. Ultrasound revealed hepatorenal cysts consistent with adult type polycystic kidney disease (ATPKD) and a cytologically confirmed left kidney tumor. Nephrectomy specimen contained sharply demarcated lesion of unusual morphology. Tubular and cystic structures lined by mostly cuboidal cells and filled with amorphous eosinophillic material, reminiscent of follicular carcinoma of the thyroid gland, were diagnostic for TLFC. Thyroid markers were negative. To our knowledge this is the first report of TFLC associated to ATPKD. Brief review of previously published TFLCs, possible relationship between entities and differential diagnosis are discussed.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/8067946569612694.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751076 | PMC |
| http://dx.doi.org/10.1186/1746-1596-8-108 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing the Rise in Papillary Thyroid Cancer Incidence: A 38-Year Australian Study Investigating WHO Classification Influence.
J Epidemiol Glob Health
January 2025
Centre of Environment and Population Health, School of Medicine and Dentistry, Griffith University, Nathan, QLD, 4111, Australia.
The incidence of thyroid cancer has shown marked increases globally over recent decades. This study investigated how the incidence of papillary thyroid carcinoma (PTC) subtypes and World Health Organisation (WHO) endocrine tumour classification changes have affected overall thyroid cancer incidence recorded in Australia. Using incidence data from the Australian Institute of Health and Welfare cancer registry (spanning 1982 to 2019), this descriptive epidemiological study employed joinpoint regression analysis to assess temporal trends in thyroid carcinoma incidence, focusing on PTC.
View Article and Find Full Text PDFLong-Term Outcomes in Radioiodine-Resistant Follicular Cell-Derived Thyroid Cancers Treated with [Lu]Lu-DOTAGA.FAPi Dimer Therapy.
Thyroid
January 2025
Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
The study aimed to analyze the long-term outcomes of [Lu]Lu-DOTAGA.FAPi dimer therapy in individuals diagnosed with radioiodine-resistant (RAI-R) follicular cell-derived thyroid cancer. In this retrospective study, 73 patients with RAI-R follicular thyroid carcinoma who had undergone multiple lines of previous treatments were included.
View Article and Find Full Text PDFIs classic papillary thyroid carcinoma definitely an "indolent cancer"?-a case of locally advanced classic occult papillary thyroid carcinoma: a case report.
AME Case Rep
November 2024
Department of Oncology Surgery, Qinghai University Affiliated Hospital, Xining, China.
Background: Occult papillary thyroid carcinoma (PTC) refers to the PTC accidentally found due to its occult lesions. Classic, as the most common subtype of PTC, is usually considered to have a low degree of malignancy and a favorable prognosis. Currently, the American Thyroid Association Management Guidelines adopted active surveillance (AS) as an alternative to immediate surgery in some low-risk PTC patients with less than 1 cm in diameter.
View Article and Find Full Text PDFInsights in biomarkers complexity and routine clinical practice for the diagnosis of thyroid nodules and cancer.
PeerJ
January 2025
Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), i3S-Institute for Research & Innovation in Health, Porto, Portugal.
Background: The differential diagnosis between benign and malignant thyroid nodules continues to be a major challenge in clinical practice. The rising incidence of thyroid neoplasm and the low incidence of aggressive thyroid carcinoma, urges the exploration of strategies to improve the diagnostic accuracy in a pre-surgical phase, particularly for indeterminate nodules, and to prevent unnecessary surgeries. Only in 2022, the 5th WHO Classification of Endocrine and Neuroendocrine Tumors, and in 2023, the 3rd Bethesda System for Reporting Thyroid Cytopathology and the European Thyroid Association included biomarkers in their guidelines.
View Article and Find Full Text PDFMorphological and immunohistochemical analysis in encapsulated follicular variant papillary thyroid carcinoma, invasive follicular variant papillary thyroid carcinoma and a new entity: non-invasive follicular thyroid neoplasm with papillary nuclear feature.
Pol J Pathol
January 2025
Department of Pathology, Necmettin Erbakan University Meram Faculty of Medicine, Konya, Turkey.
Thyroid cancers are the most common endocrine organ cancers. Encapsulated follicular variant papillary thyroid carcinomas (EFVPTC) are quite slow (indolent). Non-invasive follicular thyroid neoplasm with papillary nuclear feature (NIFTP) is a new entity identified as a result of studies in recent years.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!